Skip to main content

Articles

Page 25 of 61

  1. Type 2 diabetes (T2D) is associated with renal impairment and vascular endothelial dysfunction. Therefore, this pathological connection is an important therapeutic target. Recent cardiovascular and renal outco...

    Authors: Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Kazuhiro Sugimoto, Akira Kurozumi, Keiichi Torimoto, Hiroyuki Hirai and Koichi Node
    Citation: Cardiovascular Diabetology 2020 19:85
  2. We aimed to investigate the hazard of hospitalization for heart failure (hHF) according to the transitions in metabolic health and obesity status.

    Authors: You-Bin Lee, Da Hye Kim, Seon Mee Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Yong Gyu Park, Kyungdo Han and Hye Jin Yoo
    Citation: Cardiovascular Diabetology 2020 19:77
  3. A possible association could exist between type 2 diabetes mellitus (T2DM) and Coronavirus-19 (Covid-19) infection. Indeed, patients with T2DM show high prevalence, severity of disease and mortality during Cov...

    Authors: Celestino Sardu, Giuseppe Gargiulo, Giovanni Esposito, Giuseppe Paolisso and Raffaele Marfella
    Citation: Cardiovascular Diabetology 2020 19:76
  4. Although an increased arterial stiffness has been associated with traditional coronary risk factors, the risk factors and pathology of arterial stiffness remain unclear. In this study, we aimed to identify the...

    Authors: Naoto Katakami, Kazuo Omori, Naohiro Taya, Shoya Arakawa, Mitsuyoshi Takahara, Taka-aki Matsuoka, Hiroshi Tsugawa, Masahiro Furuno, Takeshi Bamba, Eiichiro Fukusaki and Iichiro Shimomura
    Citation: Cardiovascular Diabetology 2020 19:75
  5. Cardiovascular outcome trials in high-risk patients showed that some GLP-1 receptor agonists (GLP-1RA), but not dipeptidyl-peptidase-4 inhibitors (DPP-4i), can prevent cardiovascular events in type 2 diabetes ...

    Authors: Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro and Gian Paolo Fadini
    Citation: Cardiovascular Diabetology 2020 19:74
  6. Clinical trials have shown the cardiovascular protective effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the associ...

    Authors: Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao and Gwo-Ping Jong
    Citation: Cardiovascular Diabetology 2020 19:73
  7. Endothelial Progenitor cells (EPCs) has been shown to be dysfunctional in both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) leading to poor regeneration of endothelium and renal perfusion. ...

    Authors: Hassan B. Awal, Seshagiri Rao Nandula, Cleyton C. Domingues, Fiona J. Dore, Nabanita Kundu, Beda Brichacek, Mona Fakhri, Adrian Elzarki, Neeki Ahmadi, Shauna Safai, Magan Fosso, Richard L. Amdur and Sabyasachi Sen
    Citation: Cardiovascular Diabetology 2020 19:72
  8. Postprandial hyperglycemia was reported to play a key role in established risk factors of coronary artery diseases (CAD) and cardiovascular events. Serum 1,5-anhydroglucitol (1,5-AG) levels are known to be a c...

    Authors: Gong Su, Ming-Xi Gao, Gen-Ling Shi, Xi-Xi Dai, Wei-Feng Yao, Tao Zhang and Shao-Wei Zhuang
    Citation: Cardiovascular Diabetology 2020 19:71
  9. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that collectively cause an increased risk of type 2 diabetes mellitus (T2DM) and nonatherosclerotic cardiovascular disease. This study aimed to...

    Authors: Yue Gao, Yan Ren, Ying-kun Guo, Xi Liu, Lin-jun Xie, Li Jiang, Meng-ting Shen, Ming-yan Deng and Zhi-gang Yang
    Citation: Cardiovascular Diabetology 2020 19:70
  10. The effects of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on cardiac function are not fully understood. We investigated the changes in cardiac function in diabetic patients according to the presence and...

    Authors: In-Chang Hwang, Goo-Yeong Cho, Yeonyee E. Yoon, Jin Joo Park, Jun-Bean Park, Seung-Pyo Lee, Hyung-Kwan Kim, Yong-Jin Kim and Dae-Won Sohn
    Citation: Cardiovascular Diabetology 2020 19:69
  11. ABO blood groups have previously been associated with cardiovascular disease (CVD) in the general population. This study aimed to investigate the potential relationship between ABO blood groups and CVD in indi...

    Authors: Erika B. Parente, Valma Harjutsalo, Markku Lehto, Carol Forsblom, Niina Sandholm and Per-Henrik Groop
    Citation: Cardiovascular Diabetology 2020 19:68
  12. We evaluated the effect of statin use on new-onset type 2 diabetes among individuals without atherosclerotic cardiovascular disease (ASCVD) using nationally representative South Korean claims data (2002–2013, ...

    Authors: Eonji Na, Sunyoung Cho, Dae Jung Kim, Junjeong Choi and Euna Han
    Citation: Cardiovascular Diabetology 2020 19:67
  13. Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover, the EMPA-REG OUTCOME trial demonstrated ...

    Authors: Jolanda Sabatino, Salvatore De Rosa, Laura Tammè, Claudio Iaconetti, Sabato Sorrentino, Alberto Polimeni, Chiara Mignogna, Andrea Amorosi, Carmen Spaccarotella, Masakazu Yasuda and Ciro Indolfi
    Citation: Cardiovascular Diabetology 2020 19:66
  14. Type 2 diabetes mellitus is common in cardiovascular disease. It is associated with adverse clinical outcomes for patients who had undergone coronary artery bypass and valve operations. The aim of this study w...

    Authors: Shengwei Wang, Hao Cui, Keshan Ji, Changpeng Song, Changwei Ren, Hongchang Guo, Changsheng Zhu, Shuiyun Wang and Yongqiang Lai
    Citation: Cardiovascular Diabetology 2020 19:64
  15. Evidence of adverse clinical outcomes for non-vitamin K antagonist oral anticoagulant (NOACs) and warfarin in patients with atrial fibrillation (AF) and diabetes mellitus are limited. We investigated the effec...

    Authors: Yi-Hsin Chan, Hsin-Fu Lee, Pei-Ru Li, Jia-Rou Liu, Tze-Fan Chao, Lung-Sheng Wu, Shang-Hung Chang, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See and Gregory Y. H. Lip
    Citation: Cardiovascular Diabetology 2020 19:63
  16. Sleep disturbance has been significantly associated with the incidence of cardiovascular disease (CVD) in the general population. However, despite the common prevalence of sleep disturbance in patients with ty...

    Authors: Young Choi and Jae Woo Choi
    Citation: Cardiovascular Diabetology 2020 19:61
  17. Nationwide studies on contemporary trends in incidence of diabetes-related complications in Asia are lacking. We describe trends in incident coronary heart disease (CHD), stroke, heart failure, hyperglycaemic ...

    Authors: Hongjiang Wu, Eric S. H. Lau, Aimin Yang, Ronald C. W. Ma, Alice P. S. Kong, Elaine Chow, Wing-Yee So, Juliana C. N. Chan and Andrea O. Y. Luk
    Citation: Cardiovascular Diabetology 2020 19:60
  18. To assess the prognostic role of coronary collaterals in patients with type 2 diabetes mellitus (T2DM) after successful percutaneous coronary intervention (PCI) for chronic total occlusion (CTO).

    Authors: Zhen Kun Yang, Ying Shen, Yang Dai, Xiao Qun Wang, Jian Hu, Feng Hua Ding, Rui Yan Zhang, Lin Lu and Wei Feng Shen
    Citation: Cardiovascular Diabetology 2020 19:59
  19. The triglyceride and glucose index (TyG) has been proposed as a marker of insulin resistance. This study aims to evaluate the association of the TyG index with the severity and mortality of coronavirus disease...

    Authors: Huihui Ren, Yan Yang, Fen Wang, Yongli Yan, Xiaoli Shi, Kun Dong, Xuefeng Yu and Shujun Zhang
    Citation: Cardiovascular Diabetology 2020 19:58
  20. Glucagon-like peptide-1 (GLP-1) induces diuresis and natriuresis. Previously we have shown that GLP-1 activates afferent renal nerve to increase efferent renal sympathetic nerve activity that negates the diure...

    Authors: Kenichi Katsurada, Shyam S. Nandi, Hong Zheng, Xuefei Liu, Neeru M. Sharma and Kaushik P. Patel
    Citation: Cardiovascular Diabetology 2020 19:57
  21. The intracellular ROCK signaling pathway is an important modulator of blood pressure and of cardiovascular and renal remodeling when Rho-kinase activity is increased. Besides, in preclinical models of diabetes...

    Authors: Maria Paz Ocaranza, Patricio Valderas, Jackeline Moya, Luigi Gabrielli, Iván Godoy, Samuel Córdova, Paul Mac Nab, Lorena García, Luis Farías and Jorge E. Jalil
    Citation: Cardiovascular Diabetology 2020 19:56
  22. The triglyceride-glucose (TyG) index is a marker of insulin resistance (IR) and has been associated with various metabolic syndromes, cardiovascular diseases, and cerebrovascular diseases. However, limited inf...

    Authors: Ki-Woong Nam, Hyung-Min Kwon, Han-Yeong Jeong, Jin-Ho Park, Hyuktae Kwon and Su-Min Jeong
    Citation: Cardiovascular Diabetology 2020 19:53
  23. The microvascular effects of obesity should be considered in diabetic individuals for elucidating underlying mechanisms and developing targeted therapies. This study aims to determine the effect of obesity on ...

    Authors: Li Jiang, Ke Shi, Ying-kun Guo, Yan Ren, Zhen-lin Li, Chun-chao Xia, Lei Li, Xi Liu, Lin-jun Xie, Yue Gao, Meng-ting Shen, Ming-yan Deng and Zhi-gang Yang
    Citation: Cardiovascular Diabetology 2020 19:52
  24. Despite the known association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD), whether NAFLD predicts future CVD events, especially CVD mortality, remains uncertain. We evalu...

    Authors: Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim and Ji Hye Huh
    Citation: Cardiovascular Diabetology 2020 19:51
  25. The prognostic importance of an increased visit-to-visit blood pressure variability (BP-VVV) for the future development of micro- and macrovascular complications in type 2 diabetes has been scarcely investigat...

    Authors: Claudia R. L. Cardoso, Nathalie C. Leite and Gil F. Salles
    Citation: Cardiovascular Diabetology 2020 19:50
  26. Although more than one-third of the patients with acute heart failure (AHF) have diabetes mellitus (DM), it is unclear if DM has an adverse impact on clinical outcomes. This study compared the outcomes in pati...

    Authors: Min Gyu Kong, Se Yong Jang, Jieun Jang, Hyun-Jai Cho, Sangjun Lee, Sang Eun Lee, Kye Hun Kim, Byung-Su Yoo, Seok-Min Kang, Sang Hong Baek, Dong-Ju Choi, Eun-Seok Jeon, Jae-Joong Kim, Myeong-Chan Cho, Shung Chull Chae, Byung-Hee Oh…
    Citation: Cardiovascular Diabetology 2020 19:49
  27. Exenatide, a glucagon like peptide 1 analog, has been suggested to reduce the cardiovascular disease risk factors, such as body weight, blood pressure and subclinical atherosclerosis in patients with type 2 di...

    Authors: Jie Zhang, Tong-Zhang Xian, Ming-Xiao Wu, Chen Li, Qi Pan and Li-Xin Guo
    Citation: Cardiovascular Diabetology 2020 19:48
  28. The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th–25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recent...

    Authors: Oliver Schnell, Eberhard Standl, Xavier Cos, Hiddo JL Heerspink, Baruch Itzhak, Nebojsa Lalic, Michael Nauck and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2020 19:47
  29. The clear evidence of cardiovascular benefits in cardiovascular outcome trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes might suggest an effect on atherosclerotic plaque vulnera...

    Authors: Valentina Spigoni, Federica Fantuzzi, Cecilia Carubbi, Giulia Pozzi, Elena Masselli, Giuliana Gobbi, Anna Solini, Riccardo C. Bonadonna and Alessandra Dei Cas
    Citation: Cardiovascular Diabetology 2020 19:46
  30. Elevation in small dense low-density lipoprotein (sdLDL) is common in patients with diabetes mellitus (DM), which has already been reported to be associated with incidence of coronary artery disease (CAD). The...

    Authors: Jing-Lu Jin, Hui-Wen Zhang, Ye-Xuan Cao, Hui-Hui Liu, Qi Hua, Yan-Fang Li, Yan Zhang, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Ying Gao, Xiao-Lin Li, Chuan-Jue Cui, Geng Liu, Jing Sun, Qian Dong…
    Citation: Cardiovascular Diabetology 2020 19:45
  31. Growing evidences shows that fasting glucose target should be different according to their health condition in older adults with diabetes. However, there are limited data regarding the relationship between fas...

    Authors: Ji Hyun Lee, Kyungdo Han and Ji Hye Huh
    Citation: Cardiovascular Diabetology 2020 19:44
  32. Microangiopathy in type 2 diabetes (T2D) is associated with cardiovascular disease (CVD), but most relevant studies were performed > 10 years ago. CVD risk factor management has since improved. The aim of this...

    Authors: Jocelyn J. Drinkwater, Timothy M. E. Davis, Valentina Hellbusch, Angus W. Turner, David G. Bruce and Wendy A. Davis
    Citation: Cardiovascular Diabetology 2020 19:43
  33. Stress cardiovascular magnetic resonance (CMR) to screen for silent myocardial ischaemia in asymptomatic high risk patients with type 2 diabetes mellitus (DM) has never been performed, and its effectiveness is...

    Authors: Ming-Yen Ng, Wenli Zhou, Varut Vardhanabhuti, Chi-Ho Lee, Esther Yee Tak Yu, Eric Yuk Fai Wan, Kit Chan, Andrew T. Yan, Tai-Pang Ip, Kai-Hang Yiu and Bernd J. Wintersperger
    Citation: Cardiovascular Diabetology 2020 19:42
  34. To assess the impact of changes in different glucose tolerance states on risk of incident cardiovascular disease (CVD)/coronary heart disease (CHD).

    Authors: Maryam Kabootari, Mitra Hasheminia, Fereidoun Azizi, Mohammadhassan Mirbolouk and Farzad Hadaegh
    Citation: Cardiovascular Diabetology 2020 19:41
  35. Clinical and basic investigations have indicated a significant association between circulating growth differentiation factor 15 (GDF15) and cardiovascular disease; however, the relationship between GDF15 and l...

    Authors: Xingxing He, Jiaorong Su, Xiaojing Ma, Wei Lu, Wei Zhu, Yufei Wang, Yuqian Bao and Jian Zhou
    Citation: Cardiovascular Diabetology 2020 19:40
  36. Although studies have shown that waist circumference (WC) is positively associated with an increased risk of cardiovascular diseases among the normal population, few studies have investigated WC in patients wi...

    Authors: Zhenhua Xing, Zhenyu Peng, Xiaopu Wang, Zhaowei Zhu, Junyu Pei, Xinqun Hu and Xiangping Chai
    Citation: Cardiovascular Diabetology 2020 19:39
  37. Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure (HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis i...

    Authors: María Teresa Julián, Núria Alonso, Josep Lupón, Giovana Gavidia-Bovadilla, Elena Ferrer, Marta de Antonio, Jorge López-Ayerbe, Mar Domingo, Evelyn Santiago-Vacas, Elisabet Zamora, Pau Codina, Pedro Moliner, Julio Núñez, Javier Santesmases, Manel Puig-Domingo and Antoni Bayes-Genis
    Citation: Cardiovascular Diabetology 2020 19:38
  38. The prevalence of patients with concomitant cardiovascular disease and diabetes mellitus (DM) is increasing rapidly. We aimed to compare the effectiveness of current cardiac rehabilitation (CR) programs across...

    Authors: Prisca Eser, Thimo Marcin, Eva Prescott, Leonie F. Prins, Evelien Kolkman, Wendy Bruins, Astrid E. van der Velde, Carlos Peña-Gil, Marie-Christine Iliou, Diego Ardissino, Uwe Zeymer, Esther P. Meindersma, Arnoud. W. J. Van’tHof, Ed P. de Kluiver, Markus Laimer and Matthias Wilhelm
    Citation: Cardiovascular Diabetology 2020 19:37
  39. The present cohort study aims to examine the relationship between fibrinogen (Fib) levels and glucose metabolism [fasting blood glucose (FBG) and hemoglobin A1c (HbA1c)] and investigate the impact of high Fib ...

    Authors: Shuo-Lin Liu, Na-Qiong Wu, Hui-Wei Shi, Qian Dong, Qiu-ting Dong, Ying Gao, Yuan-Lin Guo and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2020 19:36
  40. Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds tru...

    Authors: Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, Giuseppe Bellastella, Carlo Garofalo, Paolo Chiodini, Antonio Ceriello and Katherine Esposito
    Citation: Cardiovascular Diabetology 2020 19:35
  41. Data on the relationship between the triglyceride glucose (TyG) index and coronary artery calcification (CAC) progression is limited. This longitudinal study evaluated the association of TyG index with CAC pro...

    Authors: Ki-Bum Won, Eun Ji Park, Donghee Han, Ji Hyun Lee, Su-Yeon Choi, Eun Ju Chun, Sung Hak Park, Hae-Won Han, Jidong Sung, Hae Ok Jung and Hyuk-Jae Chang
    Citation: Cardiovascular Diabetology 2020 19:34
  42. The proprotein convertase subtilisin/kexin type 9 (PCSK9) acts via a canonical pathway to regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL receptor (LDLR) on the live...

    Authors: Ying Tang, Sheng-Lan Li, Jia-Hui Hu, Kai-Jun Sun, Lei-Ling Liu and Dan-Yan Xu
    Citation: Cardiovascular Diabetology 2020 19:33
  43. Biomarkers may contribute to our understanding of the pathophysiology of various diseases. Type 2 diabetes (T2D) and coronary heart disease (CHD) share many clinical and lifestyle risk factors and several biom...

    Authors: Cornelia Huth, Alina Bauer, Astrid Zierer, Julie Sudduth-Klinger, Christa Meisinger, Michael Roden, Annette Peters, Wolfgang Koenig, Christian Herder and Barbara Thorand
    Citation: Cardiovascular Diabetology 2020 19:32
  44. The triglyceride glucose (TyG) index, a simple surrogate estimate of insulin resistance, has been demonstrated to predict cardiovascular (CV) disease morbidity and mortality in the general population and many ...

    Authors: Xiaoteng Ma, Lisha Dong, Qiaoyu Shao, Yujing Cheng, Sai Lv, Yan Sun, Hua Shen, Zhijian Wang, Yujie Zhou and Xiaoli Liu
    Citation: Cardiovascular Diabetology 2020 19:31
  45. Studies specifically examining the association between glycated hemoglobin A1c (HbA1c) levels and ischemic stroke/systemic thromboembolism (IS/SE) risk in atrial fibrillation (AF) patients are limited. Here, w...

    Authors: Yi-Hsin Chan, Chi Chuang, Cze-Ci Chan, Hsin-Fu Lee, Ya-Chi Huang, Yu-Tung Huang, Shang-Hung Chang, Chun-Li Wang, Tze-Fan Chao, Chi-Tai Kuo, Yung-Hsin Yeh and Shih-Ann Chen
    Citation: Cardiovascular Diabetology 2020 19:30
  46. The study regarding load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction is very interesting. But there are a few thing...

    Authors: Bo Liang, Yu-Xiu Zhao and Ning Gu
    Citation: Cardiovascular Diabetology 2020 19:29

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions